Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease

Clinical Outcomes of Palliative Surgery Including a Systemic-to-Pulmonary Artery Shunt in Infants With Cyanotic Congenital Heart Disease

“…17,18 ASA has established benefits in adult patients with unstable angina, cerebrovascular disease, and peripheral arterial disease by reducing atherothrombotic events across a wide range of high-risk patients (relative risk reduction, Ϸ25%). 19,20 ASA use in the present study was associated with a lower risk of death and shunt thrombosis in infants with systemic-to-pulmonary artery shunts. Low-dose ASA (Յ 1 ⁄4 baby ASA; 20 mg) and high-dose ASA (Ն 1 ⁄2 baby ASA; 40 mg) appeared to be equally protective.…”

Peripheral vascular disease endovascular management in patients scheduled for cardiac surgery: a clinical-angiographic approach

“…As matter of fact, for stent diameter ‡4.5-5 mm we can expect a low early thrombosis or restenosis rate regardless the antiplatelet regimen used. Moreover, our data did not refer to the general antiplatelet regimen in patients with peripheral vascular disease: literature data suggest that double antiplatelet regimen seems to cover patients with peripheral vascular disease from major cardiovascular events [20]. However, despite these limitations, our preliminary observations suggests that endovascular treatment of PVD in patients scheduled for urgent cardiac surgery may be effective, relatively safe and lasting in spite of low dose antiplatelet regimen even in patients with an high risk profile using a clinical and angiographic-guided approach: obviously, further larger studies should be performed in order to fully evaluate the impact over long-term outcomes of this strategy.…”

Antiplatelet therapy and prevention of ischaemic events: CAPRIE

“…17 The addition of dipyridamole to aspirin was not shown to produce additional reductions in serious vascular events 1 and although there was some reduction in stroke from the ESPS-2 study, 14 this was not consistent with the findings for non-fatal stroke, MI or vascular death in other studies. 15 As we have seen, the overall safety profile for clopidogrel was at least as good as aspirin in CAPRIE, but both drugs carry a risk of GI bleeding. (Aspirin roughly doubles the risk of GI bleeding, 18 is associated with a dose-dependent increase in upper GI symptoms, upper GI bleeding and haemorrhagic stroke, and is contraindicated in patients with active erosive gastritis, peptic ulceration, previous haemorrhagic stroke.…”